OCUL
OCULAR THERAPEUTIX, INC
OCULAR THERAPEUTIX, INC (OCUL) has 14 SEC Form 4 filings (18 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jun 18, 2026.
Insiders have net sold $360K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Pravin U. Dugel
- Employees:325
- HQ:Bedford, MA, US
- IPO:2014-07-25
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$360K
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$1.8B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Waheed NadiaFirst filing | Chief Medical Officer | Sale | 14,828 | $123K | Jun 5 | SEC ↗ |
Dugel PravinFirst filing | See Remarks | Sale | 21,156 | $173K | May 28 | SEC ↗ |
Kaiser PeterFirst filing | Chief Development Officer | Sale | 2,967 | $24K | May 28 | SEC ↗ |
Nayak SanjayFirst filing | Chief Strategy Officer | Sale | 1,858 | $15K | May 28 | SEC ↗ |
Heier Jeffrey S.First filing | Chief Scientific Officer | Sale | 3,018 | $25K | May 28 | SEC ↗ |
Related companies
OCULAR THERAPEUTIX, INC is in the Healthcare sector.